Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Malignant Solid Tumour × DOXO-EMCH × Other solid neoplasm × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Metastatic Solid Tumors 1 Malignant Solid Tumour 1 Advanced Solid Tumors 1 Advanced Solid Tumor 1

Interventions

Vorinostat 2 pembrolizumab 1 nintedanib 1 dactolisib 1 avelumab 1 Vinorelbine 1 Sunitinib 1 Oxaliplatin 1 Levoleucovorin 1 Leucovorin 1 Hydroxychloroquine 1 Folfox protocol 1 Fluorouracil 1 Dasatinib 1 DOXO-EMCH 1 Cetuximab 1 Bevacizumab 1 BN 80927 1 ARQ 197 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01337505 2022-02-10

Safety and Maximum Tolerated Dose (MTD) Study of INNO-206 in Subjects With Advanced Solid Tumors

ImmunityBio, Inc.

Phase 1 Completed

Other solid neoplasm

Malignant Solid Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡